Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics

Antimicrob Agents Chemother. 2000 Jul;44(7):1789-95. doi: 10.1128/AAC.44.7.1789-1795.2000.

Abstract

Quinupristin-dalfopristin (Q-D) is an injectable streptogramin active against most gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). In experimental endocarditis, however, Q-D was less efficacious against MRSA isolates constitutively resistant to macrolide-lincosamide-streptogram B (C-MLS(B)) than against MLS(B)-susceptible isolates. To circumvent this problem, we used the checkerboard method to screen drug combinations that would increase the efficacy of Q-D against such bacteria. beta-Lactams consistently exhibited additive or synergistic activity with Q-D. Glycopeptides, quinolones, and aminoglycosides were indifferent. No drugs were antagonistic. The positive Q-D-beta-lactam interaction was independent of MLS(B) or beta-lactam resistance. Moreover, addition of Q-D at one-fourth the MIC to flucloxacillin-containing plates decreased the flucloxacillin MIC for MRSA from 500 to 1,000 mg/liter to 30 to 60 mg/liter. Yet, Q-D-beta-lactam combinations were not synergistic in bactericidal tests. Rats with aortic vegetations were infected with two C-MLS(B)-resistant MRSA isolates (isolates AW7 and P8) and were treated for 3 or 5 days with drug dosages simulating the following treatments in humans: (i) Q-D at 7 mg/kg two times a day (b.i.d.) (a relatively low dosage purposely used to help detect positive drug interactions), (ii) cefamandole at constant levels in serum of 30 mg/liter, (iii) cefepime at 2 g b.i.d., (iv) Q-D combined with either cefamandole or cefepime. Any of the drugs used alone resulted in treatment failure. In contrast, Q-D plus either cefamandole or cefepime significantly decreased valve infection compared to the levels of infection for both untreated controls and those that received monotherapy (P < 0.05). Importantly, Q-D prevented the growth of highly beta-lactam-resistant MRSA in vivo. The mechanism of this beneficial drug interaction is unknown. However, Q-D-beta-lactam combinations might be useful for the treatment of complicated infections caused by multiple organisms, including MRSA.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Cefamandole / blood
  • Cefamandole / therapeutic use
  • Cefepime
  • Cephalosporins / blood
  • Cephalosporins / therapeutic use
  • Disease Models, Animal
  • Drug Resistance, Microbial
  • Drug Resistance, Multiple
  • Drug Therapy, Combination / blood
  • Drug Therapy, Combination / therapeutic use
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / metabolism
  • Endocarditis, Bacterial / mortality
  • Humans
  • Lincosamides
  • Macrolides*
  • Microbial Sensitivity Tests
  • Rats
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / metabolism
  • Staphylococcal Infections / mortality
  • Staphylococcus aureus / drug effects
  • Time Factors
  • Virginiamycin / blood
  • Virginiamycin / pharmacology
  • Virginiamycin / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Lincosamides
  • Macrolides
  • Virginiamycin
  • quinupristin-dalfopristin
  • Cefamandole
  • Cefepime